Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics is viewed favorably because its lead assets now have clearer, more credible regulatory and clinical paths, especially OPGx-BEST1 after encouraging Phase 1/2 data and FDA alignment on a more achievable responder definition, while OPGx-LCA5 has the company’s most advanced registrational opportunity with enrollment complete and dosing planned to begin in 4Q26. The pipeline also appears broader and more valuable as RDH12 is expected to enter clinical testing in 4Q26, MERTK in 1Q27, and three new programs are on track to enter clinical development by 2H27, creating multiple readouts and potential validation points in 2027. Financially, the current cash rate extends into 2029, reducing near-term funding risk and supporting the view that Opus can execute on a catalyst-rich IRD platform rather than remain a two-asset story.

Opus Genetics is highly dependent on two lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, so any clinical setback, regulatory delay, or failure to commercialize would materially undermine value. Its key evidence base remains fragile: OPGx-BEST1’s encouraging five-patient low-dose data is small, open-label, and uncontrolled, while the OPGx-LCA5 registrational trial has completed enrollment but treatment dosing has not yet begun. Financially, the company has incurred significant losses since inception, holds one partnered revenue-generating product, and may need additional capital despite a cash runway expected into 2029, leaving dilution and execution risk elevated.